# Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-composition-statement-and-corresponding-statement-of-ingredients-in-labeling-in-ndas-and-andas/a430f093-c9f8-4001-aef8-771d98ffdbf0

> FDA guidance document: Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs. Issue date: April 29, 2024. Get complete insights and analysis.

---

## Details

- Title: Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-04-29
- Comment Close Date: 2024-06-28
- Last Changed: 2024-04-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-1461">FDA-2024-D-1461</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Data Integrity for In Vivo Bioavailability and Bioequivalence Studies](https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b)
- [Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/statement-of-identity-and-strength-content-and-format-of-labeling-for-human-nonprescription-drug-products/eedd66d7-1c8a-4071-8ce6-a53c3f8790a3)